Results A total of 280 patients with  PDGFRA -mutant (172 D842V-mutant and 108 non-D842V-mutant) GIST after complete resection were enrolled.

The NeoTRIP trial included 280 patients with early high-risk (T1cN1; T2N1; T3N0) or locally advanced (T3N1; T4a, b, c; T4d any N; any T and N2–3) TNBC.

The objective response rate was 32.2% among the 276 response-evaluable NSCLC patients, 39.3% among the 280 melanoma patients, and 26.2% among the 126 with genitourinary tumors.

The phase 3 trial investigators recruited 280 Chinese patients who had progressed during or after first-line platinum-based chemotherapy for locally advanced or metastatic disease and randomly assigned them to receive either intravenous sintilimab 200 mg or docetaxel 75 mg/m 2 every 3 weeks.

In the phase 3 study, pembrolizumab 200 mg or placebo was administered to 278 and 280 patients, respectively, in addition to carboplatin plus paclitaxel or nab-paclitaxel every 3 weeks for 4 cycles, after which pembrolizumab or placebo were administered alone for 31 remaining cycles.

The patients with ALCL received oral crizotinib twice daily at doses of 165 mg/m 2 (ALCL165 group; n=6) or the recommended phase II dose of 280 mg/m 2 (ALCL280 group; n=20), while those with IMT received the drug at a dose of 100, 165, or 280 mg/m 2 .

The 87 Spanish patients included in the study had all achieved disease control with first-line cisplatin and gemcitabine chemotherapy and were randomly assigned to receive vinflunine 320 mg/m 2 or 280 mg/m 2 (based on Eastern Cooperative Oncology Group performance status, age, previous pelvic radiotherapy, creatinine clearance, and liver metastases) every 21 days plus best supportive care, or best supportive care alone.